Skip to content
OpenCapital
Get started

Madrigal Pharmaceuticals, Inc. MDGL Q2 2025 earnings

Reported August 5, 2025 · Before market open

Revenue$212.8MMiss by $30.7M
EPS-$1.90Beat by $1.58
Revenue estimate$243.5M
EPS estimate-$3.48

Next report

Jul 30, 2026 (Tomorrow)
Revenue estimate$351.4M
EPS estimate-$2.66

Financials

Q2 2025

Income statement

See full
Revenue$212.8M+1,354%
Operating income-$47.2M+71.0%
Net income-$42.3M+72.2%
EPS (diluted)-$1.50+78.9%

Balance sheet

See full
Cash & equivalents$191.2M-61.7%
Total debt$135.6M+3.6%
Total equity$696.0M-18.8%
Total assets$1.0B-7.7%

Cash flow

See full
Operating cash flow-$47.1M+65.1%
CapEx--100%
Free cash flow-$47.1M+65.2%

Valuation & ratios

Valuation

as of 06/30/25
See full
Market cap$6.33B+6.0%
Enterprise value$6.27B+12.0%
P/S12.3×-396×

Profitability

See full
Operating margin-60.1%-29.8pp
Net margin-54.7%-27.1pp
FCF margin-59.8%-29.6pp

Returns & leverage

See full
Return on equity-36.3%-14.4pp
Debt / equity0.2×0.0×
Current ratio5.1×-3.6×

Segments

By segment

See full
Reportable Segment$212.8M+1,354%

Versus estimates

Revenue

Q1 2026$311.3MBeat by $10.3MQ4 2025$321.1MBeat by $8.6MQ3 2025$287.3MBeat by $42.3M
Q2 2025$212.8MMiss by $30.7M
Q1 2025$137.3MMiss by $21.7MQ4 2024$103.3MBeat by $5.5M

Diluted EPS

Q1 2026-$3.25Beat by $0.36Q4 2025-$2.57Miss by $2.61Q3 2025-$5.08Miss by $3.04
Q2 2025-$1.90Beat by $1.58
Q1 2025-$3.32Beat by $0.30Q4 2024-$2.71Beat by $1.61

Ask the moment Madrigal Pharmaceuticals, Inc. reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Madrigal Pharmaceuticals, Inc. report Q2 2025 earnings?
Madrigal Pharmaceuticals, Inc. (MDGL) reported Q2 2025 earnings on August 5, 2025 before market open.
What were Madrigal Pharmaceuticals, Inc.'s Q2 2025 revenue and EPS?
Madrigal Pharmaceuticals, Inc. reported revenue of $212.8M and eps of $-1.90 for Q2 2025.
Did Madrigal Pharmaceuticals, Inc. beat estimates in Q2 2025?
Revenue missed the consensus estimate of $243.5M by $30.7M. EPS beat the consensus estimate of $-3.48 by $1.58.
How did Madrigal Pharmaceuticals, Inc.'s Q2 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 1353.8% from $14.6M a year earlier and eps grew 73.2% from $-7.10.
Where can I find Madrigal Pharmaceuticals, Inc.'s Q2 2025 SEC filings?
You can read the 10-Q periodic report (0001628280-25-037613) directly on SEC EDGAR. The filing index links above go to sec.gov.